NEW YORK (GenomeWeb) – Tauriga Sciences said on Thursday that it completed a $600,000 private placement with unnamed institutional and accredited individual investors.

The proceeds will be directed in part to advance the commercialization of the synthetic biology technology platform of its wholly owned subsidiary, Pilus Energy, for industrial wastewater remediation. The platform, called the Electrogenic Bioreaction system, harnesses genetically enhanced bacteria.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.

Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.

The Associated Press reports Alex Azar, the new Department of Health and Human Services secretary nominee, made millions of dollars as a pharmaceutical executive.

In PNAS this week: immune profiling of breast cancer, transposable element patterns in rice, and more.